Clinical Features of Cushing’s Syndrome

2010 ◽  
pp. 53-64
Author(s):  
Oscar D. Bruno
2010 ◽  
Vol 95 (5) ◽  
pp. 2262-2265 ◽  
Author(s):  
K. Mullan ◽  
N. Black ◽  
A. Thiraviaraj ◽  
P. M. Bell ◽  
C. Burgess ◽  
...  

Abstract Context: Subclinical Cushing’s syndrome has been described among diabetic populations in recent years, but no consensus has emerged about the value of screening. Methods: We enrolled 201 consecutive patients attending our diabetes clinic and 79 controls. Patients with at least two of the following three criteria were offered screening using a 2300 h salivary cortisol test: glycosylated hemoglobin of at least 7%, body mass index of at least 25 kg/m2, and a history of hypertension or blood pressure of at least 140/90 mm Hg. Results are expressed as mean ± sem. Results: Mean nighttime salivary cortisol levels were similar in the two groups (8.5 ± 1.0 nmol/liter for diabetic patients vs. 5.8 ± 1.0 nmol/liter for controls). Forty-seven patients (23%) had a value of at least 10 nmol/liter, which was set as a conservative threshold above which further investigation would be performed. Thirty-five (75%) agreed to further testing with a 1-mg overnight dexamethasone test. Of the remaining 12 patients, 10 were followed up clinically for at least 1 yr, and no evidence was found of the syndrome evolving. In 28 patients, serum cortisol suppressed to 60 nmol/liter or less. Of the seven patients who failed this test, four agreed to a 2 mg/d 48-h dexamethasone test, with serum cortisol suppressing to 60 nmol/liter or less in all four. Three declined this test but had normal 24-h urinary free cortisol levels. No patient had clinical features of hypercortisolism. Conclusions: The 1–3% detection rates of three recently published series have not been realized at our center where we studied a group using criteria making patients more likely to have hypercortisolism. Our results do not support the validity of screening patients without clinical features of Cushing’s syndrome in the diabetes clinic.


1998 ◽  
Vol 83 (8) ◽  
pp. 2681-2686 ◽  
Author(s):  
Hershel Raff ◽  
Jonathan L. Raff ◽  
James W. Findling

abstract The clinical features of Cushing’s syndrome (such as obesity, hypertension, and diabetes) are commonly encountered in clinical practice. Patients with Cushing’s syndrome have been identified by an abnormal low-dose dexamethasone suppression test, elevated urine free cortisol (UFC), an absence of diurnal rhythm of plasma cortisol, or an elevated late-night plasma cortisol. Because the concentration of cortisol in the saliva is in equilibrium with the free (active) cortisol in the plasma, measurement of salivary cortisol in the evening (nadir) and morning (peak) may be a simple and convenient screening test for Cushing’s syndrome. The purpose of this study was to evaluate the usefulness of the measurement of late-night and morning salivary cortisol in the diagnosis of Cushing’s syndrome. We studied 73 normal subjects and 78 patients referred for the diagnosis of Cushing’s syndrome. Salivary cortisol was measured at 2300 h and 0700 h using a simple, commercially-available saliva collection device and a modification of a standard cortisol RIA. In addition, 24-h UFC was measured within 1 month of saliva sampling. Patients with proven Cushing’s syndrome (N = 39) had significantly elevated 2300-h salivary cortisol (24.0 ± 4.5 nmol/L), as compared with normal subjects (1.2 ± 0.1 nmol/L) or with patients referred with the clinical features of hypercortisolism in whom the diagnosis was excluded or not firmly established (1.6± 0.2 nmol/L; N = 39). Three of 39 patients with proven Cushing’s had 2300-h salivary cortisol less than the calculated upper limit of the reference range (3.6 nmol/L), yielding a sensitivity of 92%; one of these 3 patients had intermittent hypercortisolism, and one had an abnormal diurnal rhythm (salivary cortisol 0700-h to 2300-h ratio <2). An elevated 2300-h salivary cortisol and/or an elevated UFC identified all 39 patients with proven Cushing’s syndrome (100% sensitivity). Salivary cortisol measured at 0700 h demonstrated significant overlap between groups, even though it was significantly elevated in patients with proven Cushing’s syndrome (23.0 ± 4.2 nmol/L), as compared with normal subjects (14.5± 0.8 nmol/L) or with patients in whom Cushing’s was excluded or not firmly established (15.3 ± 1.5 nmol/L). Late-night salivary cortisol measurement is a simple and reliable screening test for spontaneous Cushing’s syndrome. In addition, late-night salivary cortisol measurements may simplify the evaluation of suspected intermittent hypercortisolism, and they may facilitate the screening of large high-risk populations (e.g. patients with diabetes mellitus).


2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Ahmed Imran Siddiqi ◽  
Muhammad Usamah Bin Noor

Cushing’s syndrome remains an uncommon diagnosis with majority of non-specific and few specific clinical features suggestive of the condition. Results of biochemical investigations are often affected by confounding factors making diagnosis of Cushing’s syndrome difficult and localisation of the disease even more challenging. Careful assessment of the individual patient and use of the most suitable test in that patient may allow improved outcome in diagnosing and localising the condition to devise an appropriate management plan.Key words: Cushing’s syndrome, hypercortisolism, dexamethasone suppression test, Pseudo-Cushing’s


Author(s):  
John Newell-Price ◽  
Alia Munir ◽  
Miguel Debono

Endogenous Cushing’s syndrome results from chronic, excessive, and inappropriately high cortisol exposure. It comprises a large group of signs and symptoms. Pseudo-Cushing’s syndrome is a state of hypercortisolaemia that may have some of the clinical features of Cushing’s syndrome, but the clinical and biochemical features resolve when the underlying condition is treated: causes include alcohol dependence and depression.


Sign in / Sign up

Export Citation Format

Share Document